However, the FDA added a warning to testosterone product labeling after reviewing five observational studies and two meta-analyses of RCTs that examined the effects of testosterone therapy on MACE. Individual pellets consist of 75 mg of testosterone and may be combined to deliver variable doses of testosterone therapy. Although the absolute risks of POME and anaphylaxis require ongoing study, data from 342 patients undergoing 3,022 injections (1,000 mg in 4 mL) over a period of 3.5 years demonstrated that POME occurred after 1.9% of injections (12% of patients experienced at least one POME), with coughing episodes lasting 1-10 minutes in duration.443 All episodes were managed conservatively in the clinic, with no supplemental oxygen required. For trough total testosterone values 300 ng/dL are achieved at the end of an injection period. In contrast to topical agents where a percentage of men have difficulty achieving therapeutic levels within standard dosing ranges, injectable testosterone preparations are able to achieve therapeutic levels in almost any clinical scenario. Likewise, there might be value in defining the trough level (measured prior to injection on day one) to ensure patients remains therapeutic throughout the entire cycle. Similar to the 2.5 mg/day and 5.0 mg/day systems, peak T levels occurred 8 h post‐application, mimicking diurnal variation when the patch is applied at night. The recommended dose of IM TU is an initial 750 mg injection, followed by 750 mg 4 weeks later, and 750 mg every 10 weeks thereafter, injected in the gluteus medius.40 The manufacturer of TE, supplied as 5 ml (200 mg/ml) in sesame oil and available in multiple‐dose vials, recommends that the starting dose of IM TE injections be 50 to 400 mg every 2 to 4 weeks.37 In an open‐label, single‐arm, dose‐blinded, 52‐week phase 3 study, 150 patients were initiated on 75 mg SC TE administered weekly, with trough‐concentration‐guided dose adjustment.31 At baseline, TT was 8.0 ± 3.3 nmol/L (230.4 ± 94.0 ng/dl). Three patients developed erythrocytosis that resulted in their discontinuation from the study (29). Four participants reported small, painless nodules that resolved within 2 days, while 2 participants developed urticaria at the injection site within a few hours that persisted for up to 3 days. Local and systemic adverse events during subcutaneous administration of testosterone esters (number of events in parenthesis) Table 3 summarizes the local and systemic adverse effects reported by studies that administered testosterone esters via SC. In addition, there is no risk of sciatic injury, administration can be accomplished using smaller needles, and the pain evoked during SC administration is usually lower. The main benefit of using the SC route for administration of testosterone esters over the traditional IM route is the ease of self-administration. Mean A, 5-dihydrotestosterone (DHT) and B, estradiol (E2) concentrations on weekly subcutaneous (SC) injections of 75 mg testosterone enanthate. Combining all four doses on day 112, Cavg and Cmax levels were 19.5 nmol/L (561 ng/dl) and 29.3 nmol/L (845 ng/dl), respectively.63 Mean E2 mirrored changes observed in TT levels, but LH, FSH, and sex hormone binding globulin (SHBG) significantly decreased from baseline following T gel use. For all treatment regimens, peak T levels occurred at the first month after pellet insertion; serum T levels gradually declined to baseline by 6 months for the two 600 mg regimens, but remained significantly elevated after 6 months at the 1200 mg dose. Testosterone Replacement Therapy (TRT) is a medical intervention designed to restore testosterone levels in individuals with deficiencies, aiming to enhance both physical and psychological health…. Achieving stable levels is all about tailoring injection dose and frequency according to need, and titrating that level up or down according to both qualitative and quantitve markers. It also makes sense that the action of this variable should be predictable, something that has been demonstrated with testosterone enanthate; oestradiol and DHT levels exhibit saturable increases with increased dose(9). Hypogonadism has more recently been used interchangeably with the idea of low testosterone production alone. Commercially manufactured testosterone products should be prescribed rather than compounded testosterone, when possible. Clinicians should not prescribe alkylated oral testosterone. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. This is 1.5-2xs the half-life, which is 12 to 16 days. Overall, the regimen aligns with the pharmacokinetics of testosterone cypionate. Data sharing is not applicable to this article because no data sets were generated or analyzed during the present study. In the authors’ clinical experience, a 23-gauge needle can be used without difficulty both for long- and ultralong-acting testosterone esters. The treatment and placebo arms did not differ at baseline in terms of age (62.9 years versus 64.4 years, respectively), total testosterone level (320 ng/dL versus 344 ng/dL, respectively), or PSA measurements (1.3 ng/mL in both arms). Overall, seven studies reported no benefits on QoL in men using testosterone therapy compared to placebo,199, 205, 212, 225, 226, 230, 303, 318 while five studies demonstrated improvements.203, 317, 319, 328, 329 The impact of testosterone therapy on QoL in men with testosterone deficiency is challenging to quantify due to variable study methodology and inherent limitations with standardized questionnaires. The authors conducted a retrospective analysis of 6,355 Medicare beneficiaries who had at least 1 testosterone injection (mean number of injections over the entire study period 8.2) and matched them to 19,065 men who were testosterone therapy naïve for the preceding 12 months. Other limitations included the possible subjective nature in reporting some adverse events.Conversely, the Shores, 367 Muraleedharan,233 and Baillargeon373 studies determined that there was no increased risk of MACE in men who were on testosterone therapy. The authors compared the relative risk ratio (RRR) of developing a myocardial infarction within 90 days of receiving a testosterone or PDE5 inhibitor prescription compared to the year prior when patients were not using any medication.
